Michael H. Bar, MD

Director of Benign and Malignant Hematology at Bennett Cancer Center at Stamford Health

Hematology Oncology PC

One Hospital Plaza
Stamford, CT 06902

Main: (203) 276-2695
Fax: (203) 975-7842

About Me

Dr. Michael Bar has over 30 years of experience caring for patients with hematologic (blood) diseases. He combines a scientific approach, compassion and humor to deliver advanced, personalized care.

Dr. Bar chose to specialize in hematology so he could combine his love of patient care and scientific research, helping his patients take advantage of the latest exciting bench-to-bedside research. He enjoys meeting the intellectual challenges of his job and providing a positive, nurturing environment for his patients.

Before joining Bennett Cancer Center at Stamford Health, Dr. Bar worked at University of California San Francisco Moffitt Hospital as well as Columbia Presbyterian Medical Center. For over 20 years, Dr. Bar has been recognized for his excellent patient care and named to Castle Connelly’s Best Doctors in America, Best Doctors in New York Metropolitan Area and Best Doctors in Fairfield County. He was also awarded the Melville C. Magida Award for Best Young Physician in Fairfield County in 1994.

Dr. Bar has been married for over 30 years. In his free time, he enjoys skiing, fly fishing and listening to blues music.

icon globe



icon operation


Medical Oncology

icon doctor

special interests

  • Hematology
  • Multiple myeloma
  • Non-Hodgkins lymphoma
  • Hodgkins lymphoma
  • Acute and chronic leukemia
  • Bleeding and clotting disorders


icon education

Education & Training

Medical School

Columbia University College of Physicians and Surgeons


Moffitt Hospital-University of California


New York Presbyterian Hospital


New York Presbyterian Hospital

icon award


Published Work

Bar MH, Hawkins MJ, Mier JW, Wiernik P, Fisher RI, Coltman CA, Doroshow JH, Aronson FR, Sznol M, Atkins MB, Dutcher J. McMannis JD, Weiss GR, Margolin KA. Metastatic Malignant Melanoma Treated with a Hybrid Regimen of Bolus and Continuous Infusion Interleukin-2 and Lymphokine-Activated Killer Cells. J. Clin. Oncol. Vol. 8. 1990. pp 1138-1147.

Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH, Gucalp R, Boldt DH, Mills B, Hawkins MJ. Therapy of Renal Cell Carcinoma with Interleukin-2 and Lymphokine-Activated Killer Cells: Phase II Experience with a Hybrid Bolus and Continuous Infusion IL-2 Regimen. J. Clin. Oncol. Vol. 8. 1990. No 16304636.

Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grimer KM, Fisher RI, Boldt DH, Doroshow JH, Bar MH, Hawkins MJ, Mier JW, Caliendo G. Phase I Study of

High-Dose Continuous Infusion Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients with Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma. J. Natl. Cancer Inst. Vol. 82. No.17. September 5, 1990. pp.1397-1402.

Sznol M, Mier JW, Sporano J, Gaynor E, Weiss G, Margolin K, Bar MH, Hawkins MJ, Atkins M, Dutcher JP, Fisher Fl, Boldt DH, Doroshow JH, Louis A, Aronson FR. A Phase I Study of High-Dose Interleukin-2 in Combination with Interferon-Alpha 2B. J. Biol. Response Mod. 1990. 9:529-537.

Dutcher JP, Gaynor E, Boldt DH, Doroshow J, Bar MH, Sznol M, Mier J, Sparano J, Fisher R, Weiss G, Margolin K, Aronson FR, Hawkins M, Atkins M. A Phase II Study of High-Dose Continuous Infusion Interleukin-2 with Lymphokine-Activated Killer Cells in Patients with Metastatic Melanoma. J. Clin. Oncol. Vol. 9. 1991. pp.641-648.

Margolin KA, Aronson R, Sznol M, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Bar MH, Hawkins MJ, Gaynor EP, Boldt DH. Phase II Trial of High-Dose Interkeukin-2 and Cytokine-Activated Killer Cells in Hodgkin 's Disease and non-Hodgkin ’s

Lymphoma. J. Immunotherapy. 1991. 10(3), pp. 214-220.

Saxon RR, Kelin JS, Bar MH, Blane P, Gamsu G, Webb WR, Aronson F. Pathogenesis of Pulmonary Edema During Interleukin-2 Therapy. Correlation of Chest Radiographic and Clinical Findings in 54 Patients. Am. J. Roentgenology. 1991. 156(2), DD. 281-285.

Weiss GR, Margolin CA, Aronson FR, Sznol M, Atkins MD, Pietta E, Gaynor E, Boldt DH, Doroshow JH, Bar MH, Hawkins MJ, Mier JW, Dutcher JP, Fisher. R1: A Randomized Phase II Trial of Continuous Infusion Interleukin-2 or Bolus Injection Interleukin-2 Plus

Lymphokine-Activated Killer Cells for Advanced Renal Cell Carcinoma. J. Clin. Oncol. Vol. 10. 1992. pp. 275-281.

Amato JJ, Williams M, Greenberg C, Bar MH, Le S, Tepler I. Psychological Support to an Autologous Bone Marrow Transplant Unit in a Community Hospital: A Pilot Experience.

Psycho-Oncology. 1998. 7: 121-124.

Bar MH. The Sound and the Fury: An Update on the Role of High-Dose Chemotherapy and Autologous Stem Cell Salvage for Both Metastatic and High-Risk Breast Cancer. Connecticut

Medicine. 2000. Vol. 64, NO. 1. pp. 3-6.

D.G. Savage, N.S. Cohen, C.S. Hesdorffer, D. Heitjan, M.W. Oster, T.J. Garrett, M. Bar, S. Del Prete, R. March, M. Lonberg, S. Talbot, J.G. Mears, M. Flamm, R.N. Taub, G. Nichols. Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia. Leukemia & Lymphoma. 2003. Vol. 44 (3). pp. 477-481.

Richardson PG, Wolf J, Jakubowiak A, Leader J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Chobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardnes L, Sportelli P, Anderson KC: Perrfosine Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib: Results of a Multicenter Phase I/II Trial. J. Clin. Oncol.

29:4243-4249. 2011.

Bar MH, Aronson FR. Recombinant Human GM-CSF in Myelosuppression of Chemotherapy (continued). N. Engl. J. Med. 320(14): 939-940. 1989.

Bar MH, Valone FH, Rayner AA, Louie A, Aronson FR. A Phase I-II Trial of Combined Interleukin-2 and Vinblastine for Metastatic Renal Cell Carcinoma. Proc. Am. Assoc. Clin. Oncol.  91A568 1: 146. 1990.

Paul Richardson, MD, PhD., Jeffrey Lee Wolf, MD, Andrzej Jakubowiak, MD, PhD, Jeffrey A. Zonder, MD, Sagar Lonial, MD, David H Irwin, MD, Amrita Krishnan, MD, John Densmore, MD, Noopur Raje, MD, Michael H. Bar, MD, Robert L. Schlossman, MD, PhD, Irene Ghobrial, MD, Nikhil C. Munshi, MD, Thomas Martin, MD, Jacob Laubach, MD, Jeffrey P. Allerton, MD, Teru Hideshima, MD, PhD, Lesa Gardner, RN, Peter Sportelli, andKenneth C. Anderson, MD. Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Updated Phase I /II Trial Results. Annual Meeting Abstracts, Volume 114, Issue 22, November 20, 2009.

Board Certifications

American Board of Internal Medicine,American Board of Internal Medicine,American Board of Internal Medicine


  • American College of Physicians
  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Society for Blood and Marrow Transplantation

If You Are in Need of Emergency Care, Call 911.

The majority of the physicians on the Stamford Hospital Medical Staff are not employees or agents of the Hospital. They are independent practitioners who have been granted the privilege of using the Hospital's facilities for the care and treatment of their patients. This includes, but is not limited to, emergency department physicians, anesthesiologists, radiologists, surgeons, cardiologists, obstetricians, pathologists and other consultants who may treat patients.

Insurance listings are subject to change at any time. Please verify insurance plan acceptance when scheduling an appointment with a healthcare provider.

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.